ReviewCurrent pharmaceutical design2026
Revolutionizing Diabetic Foot Ulcer Management: Exploring the Therapeutic Potential of Natural Products.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polygenic risk meets early trauma: toward a neuropsychodevelopmental model of schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcer (DFU) is one of the most common serious complications of diabetes mellitus and often results in amputation. This complication affects 15% of individuals with diabetes over their lifetime. This review investigates the role of epigenetic modifications in DFUs, as many epigenetic mechanisms contribute to the underlying pathogenesis of diabetes and its complications, including DFUs. Therefore, initiatives aimed at understanding these epigenetic mechanisms may represent a paradigm shift in diagnosing and treating DFUs. Molecular-level studies have been conducted to identify the clinical manifestations of epigenetics in diabetes and its associated complications, such as DFU. This review synthesizes recent literature on epigenetic mechanisms contributing to diabetic foot ulcer (DFU) pathogenesis and explores the therapeutic potential of natural compounds targeting these mechanisms. Through a structured search of databases including PubMed and Scopus, we identified key natural agents, such as curcumin and resveratrol, that modulate DNA methylation, histone modifications, and non-coding RNAs. Natural compounds, which are bioactive ingredients derived from natural organisms, may serve as lead molecules and promising drug candidates, offering an excellent alternative to synthetic drugs for managing and alleviating DFUs and related complications. These natural compounds exhibit pleiotropic activities, including anti-inflammatory and antimicrobial effects, stimulation of angiogenesis, antioxidant activity, facilitation of fibroblast migration, as well as the promotion of cytokines and growth factors; therefore, they hold significant potential as valuable adjuncts to conventional therapy.
Indexed as
Identifiers
41084262What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.